ISSN: 2161-0681

Jornal de Patologia Clínica e Experimental

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Sherpa Romeu
  • Abra o portão J
  • Genâmica JournalSeek
  • JornalTOCs
  • Diretório de Periódicos de Ulrich
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Overexpression of the Novel Tumor Suppressor Gene FUS1 Suppresses the Growth of Small Cell Lung Cancer Cells

Roza Zandi, Kai Xu, Hans S. Poulsen, Jack A. Roth and Lin Ji

FUS1, also known as tumor suppressor candidate 2 (TUSC2), is a novel candidate tumor suppressor gene (TSG) frequently inactivated in human lung cancer. Loss of FUS1 protein expression is found in almost all small cell lung cancer (SCLC) cell lines and tumor specimens. Therefore, restoration of normal FUS1 function by gene transfer could serve as a potential therapeutic strategy for the treatment of SCLC. Here we investigated the effect of exogenous expression of FUS1 by plasmid-mediated gene transfer on tumor cell growth and apoptosis induction in FUS1-defective SCLC cells. Transfection of SCLC cells with wild-type FUS1 (wt-FUS1) showed in vitro growth inhibition and a marked suppression of colony formation compared to cells transfected with an empty vector (EV) or a myristoylation-defect mutant FUS1 (mt-FUS1). Forced expression of wt-FUS1 also increased the apoptotic cell population at Sub-G0/G1 in SCLC cells compared to EV- and mt-FUS1-transfected controls, which was associated with a decreased level of pro-caspase-3 and an increased level of PARP cleavage. Our results demonstrate the potential tumor suppression function of FUS1 in SCLC cells and suggest that FUS1-mediated gene therapy could be a useful therapeutic strategy for the treatment of SCLC.